{
  "event": {
    "ticker": "SVRA",
    "company": "Savara Inc.",
    "drug": "molgramostim (MOLBREEVI)",
    "application_type": "BLA",
    "indication": "Autoimmune pulmonary alveolar proteinosis (autoimmune PAP); molgramostim inhalation solution given once daily through a proprietary PARI eFlow nebulizer (drug-device combination)",
    "pdufa_date": "2026-11-22"
  },
  "display": {
    "company": "Savara",
    "drug": "molgramostim",
    "indication_en": "Autoimmune PAP",
    "indication_zh": "自身免疫性肺泡蛋白沉积症"
  },
  "probability_approval": 0.79,
  "confidence": "medium",
  "base_rate_used": 0.76,
  "key_factors": [
    {
      "factor": "The single pivotal Phase 3 trial hit its primary endpoint convincingly, and an earlier Phase 3 trial supports it",
      "direction": "+",
      "step": "medium",
      "evidence": "In IMPALA-2 (n=164, 1:1 vs placebo), the primary endpoint, change in hemoglobin-adjusted DLCO % predicted at week 24, improved by 6.0 points (p=0.0007). The gain held at week 48 (+6.9 points, p=0.0008). SGRQ total score at week 24 was also significant (-6.59, p=0.0072), but not at week 48 (p=0.10). SGRQ Activity and peak METs reached only nominal significance. Results were published in NEJM in August 2025. The earlier IMPALA Phase 3 trial gave supportive confirmatory evidence (A-aDO2 p=0.03 in a post-hoc imputation analysis; SGRQ p=0.01). When the FDA refused to file the first BLA in 2025, it did not ask for more efficacy studies.",
      "source": "SEC 10-K filed 2026-03-13; Savara RTF press release 2025-05-27"
    },
    {
      "factor": "Expedited-review signals: Breakthrough Therapy, Priority Review, and no advisory committee",
      "direction": "+",
      "step": "small",
      "evidence": "The product has Fast Track, Breakthrough Therapy and Orphan designations. The BLA was filed in February 2026 with Priority Review. The FDA's Day-74 letter said it had no plans to convene an advisory committee.",
      "source": "Savara press release 2026-03-06; SEC 10-Q filed 2026-08-11"
    },
    {
      "factor": "Benign safety profile in a disease with no approved drug",
      "direction": "+",
      "step": "small",
      "evidence": "Only 3% discontinued during the 48-week double-blind period, and no discontinuations were attributed to the trial drug. No unexpected safety signals were seen. Systemic GM-CSF (sargramostim) is a known drug class. A REMS is unlikely. The current standard of care is whole-lung lavage.",
      "source": "SEC 10-K filed 2026-03-13; SEC 8-K 2026-01-09 (investor presentation)"
    },
    {
      "factor": "Complex manufacturing: first commercial product, a drug-device combination, and a drug-substance technology transfer after a CMC refuse-to-file",
      "direction": "-",
      "step": "medium",
      "evidence": "The March 2025 BLA was refused for filing in May 2025 because CMC data were incomplete. After a Type A meeting, Savara resubmitted in December 2025, naming FUJIFILM Diosynth as the drug-substance maker in place of the clinical-supply maker, GEMA Biotech. This requires showing comparability between GEMA and Fujifilm material, supported by three PPQ batches. Drug product is made at Patheon UK (Thermo Fisher). Pre-license inspections are needed, and CDRH must review the device constituent. My searches found no 2025-26 warning letters for Fujifilm's UK or Danish sites or for Patheon UK. Filings do not name the Fujifilm site.",
      "source": "SEC 10-K filed 2026-03-13 (manufacturing strategy section); SEC 10-Q filed 2026-08-11 (manufacturing commitments)"
    },
    {
      "factor": "Three-month PDUFA extension for a major amendment; what the information requests covered was not disclosed",
      "direction": "-",
      "step": "small",
      "evidence": "In April 2026 the FDA classified Savara's responses to its information requests as a major amendment, moving the date from 2026-08-22 to 2026-11-22. The company says the FDA cited no safety, efficacy or manufacturing concerns, which is standard wording. Given the earlier CMC refusal, the requests were plausibly about CMC or comparability, but that is not confirmed. Historically, extensions are not strongly negative.",
      "source": "Savara press release 2026-04-15; SEC 10-Q filed 2026-05-12 and 2026-08-11"
    },
    {
      "factor": "Company behaviour is consistent with expecting approval",
      "direction": "+",
      "step": "small",
      "evidence": "Q2 2026 G&A rose 78% as Savara built a commercial team for a planned launch. About $150M of non-dilutive capital becomes available on FDA approval. PSUs vest on BLA approval. Recent Form 4s show only RSU grants and tax withholding, with no open-market selling.",
      "source": "SEC 10-Q filed 2026-08-11; Savara Q2 2026 results press release 2026-08-11; SEC Form 4 filed 2026-09-25"
    }
  ],
  "manufacturing_risk": {
    "level": "medium",
    "why": "This is a small company's first commercial product: an inhaled recombinant protein given with a proprietary nebulizer. The drug-substance supplier was switched from the clinical-trial maker (GEMA) to FUJIFILM Diosynth after a CMC refuse-to-file, so analytical comparability and pre-license inspections of Fujifilm and Patheon UK must pass. Both are established CDMOs with no 2025-26 warning letters found. The content of the information requests behind the major amendment is not public, so the CMC risk cannot be judged directly."
  },
  "what_would_change_my_mind": [
    "Disclosure of an FDA Form 483 or OAI classification at the Fujifilm drug-substance site or Patheon UK, or news that the major-amendment requests concerned GEMA-to-Fujifilm comparability",
    "Company disclosure of late-cycle meeting outcomes or label negotiations (positive) or new FDA information requests close to the action date (negative)",
    "An MHRA decision (expected Q4 2026) or a CHMP opinion: a positive one would be mildly reassuring on CMC, a negative one a material warning",
    "Any further PDUFA extension, which would change the date but not by itself the probability"
  ],
  "summary_en": "We put approval in this review cycle at 79%, slightly above the ~76% base rate for small/mid-cap original BLAs. The efficacy case is solid: IMPALA-2 met its primary DLCO endpoint (p=0.0007), the effect was durable at 48 weeks, SGRQ improved at week 24, and the drug has Breakthrough designation, Priority Review and no advisory committee. The main risk is manufacturing. This is a first-ever inhaled biologic and device combination; the first BLA was refused for incomplete CMC data; drug substance was moved to FUJIFILM Diosynth, which requires comparability; and a major amendment with undisclosed content pushed the date to November 22. Confidence is medium because the CMC picture is not public.",
  "summary_zh": "我们估计本轮审评获批概率为79%，略高于中小型公司原始BLA约76%的基准。疗效证据较扎实：IMPALA-2主要终点DLCO显著改善（p=0.0007），48周疗效持续，第24周SGRQ改善，并获突破性疗法认定和优先审评，且不召开专家咨询会。主要风险在生产环节：这是首个吸入用生物药与雾化器组合产品；首次BLA因CMC数据不完整被拒绝受理；原料药已转由富士胶片Diosynth生产，需证明可比性；FDA认定的重大修订内容未披露，审评期限已延至11月22日。由于CMC细节不公开，判断把握度为中等。",
  "sources": [
    "https://www.sec.gov/Archives/edgar/data/1160308/000119312526344585/svra-20260630.htm (10-Q filed 2026-08-11: PDUFA 2026-11-22, major amendment, commercial build-out, CMO commitments)",
    "https://www.sec.gov/Archives/edgar/data/1160308/000119312526219371/svra-20260331.htm (10-Q filed 2026-05-12)",
    "https://www.sec.gov/Archives/edgar/data/1160308/000119312526105076/svra-20251231.htm (10-K filed 2026-03-13: IMPALA-2 results, RTF history, Fujifilm/GEMA/Patheon/PARI supply chain)",
    "https://www.sec.gov/Archives/edgar/data/1160308/000119312526008301/d24211d8k.htm (8-K 2026-01-09, investor presentation)",
    "https://www.sec.gov/Archives/edgar/data/1160308/000119312526403070/ (Form 4 filed 2026-09-25)",
    "https://investors.savarapharma.com/news/news-details/2026/Savara-Provides-Regulatory-Update-on-the-MOLBREEVI-Development-Program-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx (2026-03-06: Day-74 letter, no AdCom)",
    "https://investors.savarapharma.com/news/news-details/2026/Savara-Announces-the-U-S--Food--Drug-Administration-FDA-Has-Extended-the-Review-Period-for-the-Molgramostim-Inhalation-Solution-Molgramostim-Biologics-License-Application-BLA-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx (2026-04-15: PDUFA extension)",
    "https://investors.savarapharma.com/news/news-details/2026/Savara-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update/default.aspx (2026-08-11: MHRA decision Q4 2026, EMA Q1 2027, ~$150M non-dilutive capital on approval)",
    "https://www.stocktitan.net/news/SVRA/savara-receives-refusal-to-file-rtf-letter-from-the-u-s-food-and-fwaasz4pu15k.html (RTF press release 2025-05-27: CMC data requested, no efficacy studies requested)",
    "https://www.biopharminternational.com/view/fda-extends-review-of-savara-s-molgramostim-bla-for-pap",
    "https://www.fda483s.com/fdadocs/fujifilm-diosynth-biotechnologies-denmark-aps-hillerod-denmark-2/ (Hillerød inspection history; no warning letter found)",
    "https://redica.com/document-store/sites/siteprofile/100060044/patheon-uk-limited-swindon-united-kingdom-of-great-britain-and-northern-ireland (Patheon UK inspection history)"
  ],
  "zh": {
    "indication": "自身免疫性肺泡蛋白沉积症（自身免疫性 PAP）；molgramostim 吸入溶液，每日一次经专有 PARI eFlow 雾化器给药（药械组合产品）",
    "key_factors": [
      {
        "factor": "唯一的关键 3 期试验以令人信服的结果达到主要终点，且有一项更早的 3 期试验提供支持",
        "evidence": "在 IMPALA-2（n=164，与安慰剂 1:1 随机）中，主要终点——第 24 周经血红蛋白校正的 DLCO 占预计值百分比的变化——改善 6.0 个百分点（p=0.0007）。该获益在第 48 周得以维持（+6.9 个百分点，p=0.0008）。第 24 周 SGRQ 总分亦达到显著（-6.59，p=0.0072），但第 48 周未达到（p=0.10）。SGRQ 活动分项和峰值代谢当量（METs）仅达到名义显著。结果于 2025 年 8 月发表于 NEJM。更早的 IMPALA 3 期试验提供了支持性确证证据（事后插补分析中 A-aDO2 p=0.03；SGRQ p=0.01）。FDA 在 2025 年拒绝受理首次提交的生物制品许可申请（BLA）时，并未要求开展更多疗效研究。"
      },
      {
        "factor": "加快审评信号：突破性疗法认定、优先审评，且不召开专家咨询委员会会议",
        "evidence": "该产品拥有快速通道、突破性疗法和孤儿药资格认定。BLA 于 2026 年 2 月获受理并获优先审评。FDA 的第 74 天函件表示不计划召开专家咨询委员会会议。"
      },
      {
        "factor": "在尚无获批药物的疾病中安全性良好",
        "evidence": "48 周双盲期内仅 3% 的患者停药，且无一例停药归因于试验药物。未观察到意外的安全性信号。全身用 GM-CSF（sargramostim）属于已知药物类别。不太可能需要风险评估与减低策略（REMS）。目前的标准治疗为全肺灌洗。"
      },
      {
        "factor": "生产复杂：首个商业化产品、药械组合产品，且在因化学、生产与控制（CMC）问题被拒绝受理后进行了原料药技术转移",
        "evidence": "2025 年 3 月提交的 BLA 于 2025 年 5 月因 CMC 数据不完整被拒绝受理。经 A 类会议后，Savara 于 2025 年 12 月重新提交，将原料药生产商由临床供应商 GEMA Biotech 更换为 FUJIFILM Diosynth。这需要证明 GEMA 与 Fujifilm 产品的可比性，并以三批工艺性能确认（PPQ）批次作为支持。制剂由 Patheon UK（Thermo Fisher）生产。需要进行批准前检查，且 CDRH 须审查器械组成部分。我的检索未发现 Fujifilm 英国或丹麦场地以及 Patheon UK 在 2025-26 年收到警告信。申报文件未指明具体的 Fujifilm 场地。"
      },
      {
        "factor": "因重大修改，PDUFA 目标日期延后三个月；信息请求的具体内容未披露",
        "evidence": "2026 年 4 月，FDA 将 Savara 对其信息请求的回复认定为重大修改，将日期从 2026 年 8 月 22 日推迟至 2026 年 11 月 22 日。公司称 FDA 未提及任何安全性、有效性或生产方面的担忧，这是标准措辞。鉴于此前曾因 CMC 被拒绝受理，这些信息请求很可能涉及 CMC 或可比性，但尚未得到证实。从历史经验看，延期并不是明显的负面信号。"
      },
      {
        "factor": "公司行为与预期获批相符",
        "evidence": "2026 年第二季度一般及行政费用（G&A）增长 78%，Savara 正为计划中的上市组建商业化团队。FDA 批准后约 1.5 亿美元非稀释性资金将可动用。PSU 在 BLA 获批时归属。近期的 Form 4 仅显示 RSU 授予及代扣税款，没有公开市场减持。"
      }
    ],
    "manufacturing_risk_why": "这是小型公司的首个商业化产品：一款经专有雾化器给药的吸入用重组蛋白。在因 CMC 问题被拒绝受理后，原料药供应商由临床试验生产商（GEMA）更换为 FUJIFILM Diosynth，因此分析可比性以及 Fujifilm 和 Patheon UK 的批准前检查都必须通过。两者均为成熟的合同生产商（CDMO），且未发现 2025-26 年的警告信。导致重大修改的信息请求内容未公开，因此无法直接判断 CMC 风险。",
    "what_would_change_my_mind": [
      "披露 Fujifilm 原料药场地或 Patheon UK 收到 FDA 483 表或被列为 OAI（需采取官方行动），或有消息称重大修改相关请求涉及 GEMA 至 Fujifilm 的可比性",
      "公司披露后期审评会议结果或说明书谈判（正面），或临近决定日期时收到 FDA 新的信息请求（负面）",
      "MHRA 的决定（预计 2026 年第四季度）或 CHMP 意见：正面结果可在 CMC 方面略添信心，负面结果则是实质性警示",
      "PDUFA 目标日期再次延期，这会改变日期，但本身不改变概率"
    ]
  },
  "recorded_at": "2026-10-04T19:58:10+00:00"
}